Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A40AEG0
Tue, 12.11.2024
Pentixapharm Holding AG
Pentixapharm Releases Interim Report for the Third Quarter of 2024
Loss of Pentixapharm Holding AG for the reporting period: €49k
No revenue realized during the stub fiscal year through the end of Q3
Current liabilities of €487k, mainly from the purchase of Pentixapharm AG shares
Berlin and Würzburg, Germany, November 12, 2024 – Pentixapharm Hol [ … ]
Mon, 04.11.2024
Pentixapharm Holding AG
Berlin and Würzburg, Germany, November 4, 2024 – Pentixapharm, a biopharmaceutical company developing innovative first-in-class radiopharmaceuticals, welcomes the recent announcement by the U.S. Centers for Medicare & Medicaid Services (CMS) to implement separate payments for specialized diagnostic radiopharmaceuticals used in the hospital outp [ … ]
Tue, 29.10.2024
Pentixapharm Holding AG
Berlin and Würzburg, Germany, October 29, 2024 – The National Cancer Institute (NCI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), two highly respected research organizations belonging to the US government's National Institutes of Health (NIH), have started a clinical trial involving 77 patients to see if Pentixa [ … ]
Mon, 28.10.2024
Pentixapharm Holding AG
Berlin, Germany, October 28, 2024 – Prof. Dr. Ken Herrmann, a distinguished scientist and Head of the Department of Nuclear Medicine at Universitätsklinikum Essen, Germany, has as of today formally assumed his seat on the Supervisory Board of Pentixapharm Holding AG. While the appointment dates back to the shareholder meeting in June 2024 and has b [ … ]
Fri, 25.10.2024
Pentixapharm Holding AG
Berlin, Germany, October 25, 2024 - Following the receipt of various approvals, consents, and registrations, Pentixapharm Holding AG will implement, at the end of October 2024, a series of changes to the group's management bodies.
As announced, Dr. Hakim Bouterfa, founder and CEO of Pentixapharm AG, will step down from his positions on the Managem [ … ]
Sat, 19.10.2024
Pentixapharm Holding AG
Hamburg, Germany, October 19, 2024 - The CXCR4 targeting compounds developed clinically by Pentixapharm in a number of diagnostic and therapeutic indications are subject of 17 abstract presentations at the 37th Annual Congress of the European Association of Nuclear Medicine (EANM) which takes place in Hamburg from 19 – 23 October 2024. The presenta [ … ]
Thu, 03.10.2024
Pentixapharm Holding AG
ADVERTISEMENT
NOT FOR DISTRIBUTION OR ANNOUNCEMENT, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR ANNOUNCEMENT WOULD BE UNLAWFUL
Press Release
Pentixapharm Holding AG Completes IPO in the Prime Standard of the Frankfurt Stock Exchange [ … ]
Mon, 23.09.2024
Pentixapharm Holding AG
ADVERTISEMENT
NOT FOR DISTRIBUTION OR ANNOUNCEMENT, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR ANNOUNCEMENT WOULD BE UNLAWFUL
Press Release
Pentixapharm Holding AG Sets Price Range for Planned IPO
Offering of up to 3.9 million new [ … ]
Mon, 23.09.2024
Pentixapharm Holding AG
ADVERTISEMENT
NOT FOR DISTRIBUTION OR ANNOUNCEMENT, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR ANNOUNCEMENT WOULD BE UNLAWFUL
Press Release
Pentixapharm Holding AG Sets Price Range for Planned IPO
Offering of up to 3.9 million new [ … ]
Thu, 12.09.2024
Pentixapharm Holding AG
ADVERTISEMENT
NOT FOR DISTRIBUTION OR ANNOUNCEMENT, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR ANNOUNCEMENT WOULD BE UNLAWFUL
Press Release
Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime [ … ]